NextPoint Therapeutics

NextPoint Therapeutics is a clinical-stage biotechnology company advancing a new world of precision immuno-oncology therapeutics through its leading scientific work on the novel B7-H7/HHLA2 immune checkpoint axis. Founded in 2019, the company is developing a pipeline of first-in-class assets including NPX372, a T-cell engager engineered with a superior therapeutic window; NPX125, an antibody-drug conjugate featuring a proprietary linker and highly potent payload; and NPX887, a multi-functional checkpoint inhibitor that blocks immune suppression and restores immune activation. The scientific foundation is built on the discovery of the HHLA2 immune checkpoint pathway in 2013 by Gordon Freeman (Dana-Farber Cancer Institute) and XingXing Zang (Albert Einstein College of Medicine). NextPoint targets cancer patients with B7-H7 upregulation, including those who do not respond to existing PD-1/L1 inhibitors, using a biomarker-driven approach to identify the right patient population for each modality. The company entered its first-in-class clinical trial targeting this pathway in 2023 and raised $122.5 million through its Series B financing. NextPoint is headquartered in Cambridge, Massachusetts and backed by investors including LEAPS by Bayer, Sanofi Ventures, Catalio Capital, Invus, and MPM BioImpact.